WO2012026575A1 - Développeur de la masse musculaire - Google Patents

Développeur de la masse musculaire Download PDF

Info

Publication number
WO2012026575A1
WO2012026575A1 PCT/JP2011/069276 JP2011069276W WO2012026575A1 WO 2012026575 A1 WO2012026575 A1 WO 2012026575A1 JP 2011069276 W JP2011069276 W JP 2011069276W WO 2012026575 A1 WO2012026575 A1 WO 2012026575A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
fish
fast
protein
walleye
Prior art date
Application number
PCT/JP2011/069276
Other languages
English (en)
Japanese (ja)
Inventor
二功 川端
辻　智子
貴文 水重
太郎 岸田
Original Assignee
日本水産株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本水産株式会社 filed Critical 日本水産株式会社
Priority to JP2012530734A priority Critical patent/JP5838161B2/ja
Publication of WO2012026575A1 publication Critical patent/WO2012026575A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/04—Animal proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a muscle strengthening agent. Moreover, this invention relates to the foodstuff which has a muscle enhancement effect.
  • Non-patent Document 2 It has been reported that supplementing food with L-arginine increases both slow and fast muscles.
  • Muscles are classified into fast muscle fibers that can be instantaneously contracted (white muscles) and slow muscle fibers that can be continuously contracted (red muscles).
  • the fast muscle can be quickly contracted and is used to extract the instantaneous force.
  • the fast muscle is a muscle often used during anaerobic exercise, and it is also called a white muscle because of its color.
  • Slow muscles are small muscles that are used to slowly contract and draw endurance.
  • the slow muscle is a muscle often used during aerobic exercise, and it is also called red muscle because of its color. Since the muscles used differ depending on the type of exercise, a food that can specifically strengthen any type of muscle is desired. However, foods and drugs that can specifically enhance either fast or slow muscle are not known. In addition, no drug or food ingredient that can change the slow muscle into a fast muscle type muscle fiber has been reported.
  • fish and shellfish-derived proteins are known to have various actions on living organisms, and many fish and shellfish-derived proteins have been studied for their effects on living organisms. For example, it has been found that the intake of fish protein suppresses the accumulation of visceral fat (Patent Document 1). In addition, fish and shellfish-derived proteins are known to improve lipid metabolism. For example, it is described that fish and shellfish-derived proteins have a blood cholesterol lowering effect (Patent Document 2). In addition, fish-derived proteins have been studied for their effects in the living body.
  • Non-patent Document 3 walleye pollack-derived protein has been reported to have an effect on cholesterol and triglycerol (Non-patent Document 3), and in rats fed with walleye pollen-derived protein, plasma was compared with rats fed casein. It has been shown that the concentration of triglycerol in the medium decreases and the concentration of cholesteryl ester in the liver increases.
  • An object of the present invention is to provide a muscle enhancer containing fish protein of fish belonging to the order of Cod. Another object of the present invention is to provide a food having muscle strengthening action.
  • the present inventors paid attention to the effect of walleye pollock fish meat protein on the physiological action and, as a result of repeated research, found that walleye pollock fish meat protein has a muscle-enhancing action and arrived at the present invention.
  • the present invention provides a fast muscle-specific muscle-enhancing agent containing fish protein of fish belonging to the order of Cod.
  • the present invention also provides a muscle strengthening agent that contains fish protein of fish belonging to the order of Codidae and changes the slow muscle to the fast muscle type.
  • the present invention also includes a food protein containing fish protein of a fish belonging to the order of a cod, and a label indicating that it has a fast muscle-specific muscle-enhancing action or a label indicating that the slow muscle is changed to a fast muscle ( Functional food).
  • the present invention also relates to a fish meat belonging to the order of a fish for producing a food with an indication that it has a fast muscle-specific muscle-enhancing effect or an indication that it has an action of changing a slow muscle to a fast muscle.
  • the present invention describes a food containing fish protein of a fish belonging to the order of the cod, that the food has a muscle strengthening action specific to fast muscles or an action to change slow muscles to fast muscles.
  • the muscle enhancer of the present invention can strengthen muscles specifically in fast muscles. Moreover, the muscle strengthening agent of this invention can change a slow muscle to a fast muscle type.
  • the muscle building agent of the present invention is useful as a nutritional drink or food for athletes who need instantaneous power. It is also useful as various drinks and various foods for preventing and / or improving muscle mass and muscle weakness (sarcopenia) associated with aging.
  • strengthening effect by walleye pollock fish protein The figure which shows the weight change of the soleus muscle by walleye pollock fish meat protein.
  • the muscle strengthening agent of the present invention contains fish protein of fish belonging to the order of Cod.
  • the fish protein may be the fish meat itself, but it is also possible to use a protein from which the lipid has been removed by a degreasing treatment.
  • a degreasing method a method such as boiling, steaming or baking, or a method such as extraction using ethanol or hexane can be used.
  • walleye pollack fish and Hoki fish meat processed in the following steps can be used as fish meat protein.
  • the walleye pollock fish meat is cut into an appropriate size, the cut sample is frozen, and then freeze-dried in a freeze dryer.
  • the freeze-dried sample is pulverized by a conventional method, and ethanol or the like is added thereto to elute the fat-soluble component.
  • ethanol or the like is added thereto to elute the fat-soluble component.
  • walleye fish protein can be obtained.
  • the intake energy can be reduced.
  • fish protein can be decomposed and used so that it can be easily absorbed.
  • proteolytic enzymes such as papain, trypsin, pepsin, bromelain, ficin and alcalase protease.
  • the fish meat used as a raw material is preferably white meat, and particularly fish protein of fish belonging to the order of Cod.
  • examples of fish belonging to the order of Codella include walleye pollock, southern bluefin, northern blue whiting, king clip, hake, madara and hoki.
  • muscle enhancement means increasing muscle mass. Muscles are classified into fast muscle fibers capable of instantaneous contraction (white muscles) and slow muscle fibers capable of continuous contraction (red muscles).
  • the muscle-enhancing agent of the present invention is fast muscle-specific. To strengthen muscles.
  • fast muscle-specific muscle enhancement means that the muscle mass of fast muscle is increased more than the total muscle mass increased when compared with various proteins. Therefore, even when muscle enhancement is specific to fast muscles, slow muscles are enhanced at the same time.
  • the muscle strengthening agent of the present invention has an action of changing the slow muscle to the fast muscle type.
  • changing the slow muscle to the fast muscle type means that when the ratio of the slow muscle and the ratio of the fast muscle are compared, the ratio of the slow muscle decreases and the ratio of the fast muscle increases. .
  • the fast muscle-specific muscle-enhancing agent and the muscle-enhancing agent that changes the slow muscle to the fast-muscle type of the present invention can be a composition containing any component in addition to the above components.
  • the fast muscle-specific muscle-enhancing agent of the present invention when used as a medicament, has a pharmaceutical composition together with a pharmaceutically acceptable base, carrier, excipient, disintegrant, lubricant and coloring agent.
  • a pharmaceutically acceptable base for example, the fast muscle-specific muscle-enhancing agent of the present invention, when used as a medicament, has a pharmaceutical composition together with a pharmaceutically acceptable base, carrier, excipient, disintegrant, lubricant and coloring agent.
  • carriers and excipients used in the pharmaceutical composition include lactose, glucose, sucrose, mannitol, potato starch, corn starch, calcium carbonate, calcium phosphate, calcium sulfate and crystalline cellulose.
  • binder examples include starch, gelatin, syrup, tragacanth gum, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, hydroxypropylcellulose, methylcellulose, ethylcellulose and carboxymethylcellulose.
  • disintegrant examples include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, sodium alginate, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium and the like.
  • lubricants include magnesium stearate, hydrogenated vegetable oil, talc and macrogol.
  • colorant any colorant allowed to be added to a pharmaceutical product can be used.
  • the pharmaceutical composition may be sucrose, gelatin, purified shellac, gelatin, glycerin, sorbitol, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, cellulose phthalate acetate, hydroxypropylmethylcellulose phthalate, methyl methacrylate. Further, it may be coated with one or more layers with a methacrylic acid polymer or the like. Moreover, you may add a pH adjuster, a buffering agent, a stabilizer, a solubilizer, etc. as needed.
  • the pharmaceutical composition can be provided as a preparation of any form.
  • the pharmaceutical composition can be prepared as an orally administered preparation, such as a sugar-coated tablet, buccal tablet, coated tablet and chewable tablet, capsules including troches, pills, powders and soft capsules, granules, suspensions, emulsions and dry syrups. It can be a liquid such as syrup and elixir.
  • the pharmaceutical composition can be administered intravenously, subcutaneously, intraperitoneally, intramuscularly, transdermally, nasally, pulmonarily, enterally, buccally, and transmucosally for parenteral administration.
  • It can be a formulation for administration, such as administration.
  • it can be an injection, a transdermal absorption tape, an aerosol, a suppository and the like.
  • the fast muscle-specific muscle-enhancing agent of the present invention and the muscle-enhancing agent that changes the slow muscle to the fast muscle type can be provided as food. That is, a food containing fish meat protein of a fish belonging to the order of Cod and having an action of enhancing muscles specific to fast muscles and an action of changing slow muscles to a fast muscle type is provided.
  • food means all foods including beverages, and includes general foods including health foods such as supplements, as well as foods for specified health use and nutritional function foods stipulated in the Health Function Food System of the Consumer Affairs Agency. Including. For example, a functional food with an indication that it has a fast muscle-specific muscle-enhancing effect or an indication that it has an effect of changing the slow muscle to a fast muscle type is provided.
  • a food containing fish protein of fish belonging to the order of Cod can be provided as it is. Also, to provide foods that are added to other foods, mixed or applied, etc., as food materials that have fast muscle-specific muscle strengthening action and action to change slow muscle to fast muscle type Can do. In addition to food, it can also be provided as cosmetics and food.
  • a food containing fish meat protein of a fish belonging to Codidae together with instructions describing that the food has a fast muscle-specific muscle-enhancing action or an action that changes the slow muscle to a fast-muscle type It can be provided as a packaged product.
  • fish protein of fish belonging to the cod eye can be used.
  • the muscle-enhancing agent and food of the present invention can contain fish protein of fish belonging to the order of cod, for example, in an amount of 100 ⁇ g to 0.999 kg / kg, preferably 10 g to 900 g / kg. .
  • fish protein of the fish belonging to the order of Codidae is not limited depending on conditions such as symptom level, patient age, weight and health condition when administered to a patient as a medicine, but for adults it is 100 ⁇ g to 10 g / kg / day, preferably 0.1 to 1 g / kg / day, can be administered orally or parenterally, divided into once or more than 2 to 4 times a day, with appropriate intervals.
  • the fish protein used in the present invention does not have a strong effect and side effects unlike pharmaceutical products, so there is no limit on the daily intake.
  • a frozen Alaskan walleye fillet (Unicy) was cut into a size of about 1 cm ⁇ 1 cm ⁇ 1 cm with a band saw (Akiyama Machine Co., Ltd., 600ST).
  • the cut samples were arranged in one layer on a freeze-drying tray, and pre-freeze for 4 hours at ⁇ 30 ° C. with a freeze dryer (manufactured by Tokyo Rika Kikai Co., Ltd., TF20-85ATNNN), followed by freeze-drying for 4 days and nights.
  • the freeze-dried sample was lightly crushed by hand and pulverized with a pin mill (manufactured by Hadano Sangyo Co., Ltd., EM-1A).
  • 5-week-old male SD rats obtained from Shimizu Experimental Materials Co., Ltd. were divided into walleye fish protein group and casein group, and were fed freely with powdered feed having the composition shown in Table 2, respectively.
  • This powdered feed is obtained from Oishi et al. (Yoshie Oishi et al., “Alaska pollack protein prevents the The same feed as described in “accumulation of visceral fat in rats fed a high fat diet”, J. Nutr. Sci. Vitaminol., 2009, 55, pp.156-161).
  • the casein contained in New Zealand Dairy Board was used as a casein, and each group consisted of 8 rats, and the rats were ingested for 4 consecutive weeks, then dissected and the tissue weight was measured. Rats received 15-30 g of food per day.
  • FIG. 1 shows the result of measuring the weight of the puffer muscle, which is representative of the fast muscle. Compared to the casein group, the weight of the calf muscle, which is representative of fast muscle, increased significantly in the walleye fish protein group.
  • walleye fish protein has fast muscle-specific muscle strengthening action.
  • Example 2 Muscle enhancement effect, muscle fiber type change and muscle metabolism change by long-term administration of the product of the present invention in rats
  • the walleye fish protein used was obtained in the same procedure as in Example 1.
  • Hoki fish meat protein was obtained from frozen New Zealand Hoki fillet (Tully's Co., Ltd.) in the same manner as in Example 1.
  • About 1.6 kg of hoki fish protein was obtained from 10 kg of frozen hoki fillet.
  • the component composition of the obtained hoki fish protein is shown in Table 3.
  • FIG. 3 and FIG. 4 show the results of measuring the weight of the puffer muscle and the long calf extensor which are representative of the fast muscle.
  • the walleye pollack fish protein group and the hoki fish protein group significantly increased the weights of the gluteal muscle and the long calf extensor muscle, which are representative of the fast muscles.
  • walleye pollack fish protein and hoki fish meat protein have fast muscle-specific muscle-enhancing effects by long-term administration.
  • the measurement results of the Myh4 gene which is an index of fast muscle fibers, are shown in FIG.
  • the expression level of the Myh4 gene was significantly increased in the walleye fish protein group compared to the casein group in the long-knee extensor muscle, which is a representative muscle of the fast muscle.
  • the soleus muscle which is the representative muscle of the slow muscle, there was no difference in Myh4 gene expression between the two groups.
  • walleye fish protein changes the muscle fiber type in a direction to make fast muscles faster.
  • Fig. 7 shows the measurement results of the Myh7 gene, which is an indicator of slow muscle fibers.
  • the expression level of the Myh7 gene was significantly decreased in the walleye fish protein group in the soleus muscle compared with the casein group. On the other hand, in the longus extensor, there was no difference in Myh7 gene expression between the two groups.
  • walleye fish protein changes the muscle fiber type in the direction of decreasing slow muscle fibers.
  • FIG. 8 shows the measurement results of the PGC1 ⁇ gene, which is an index of increased lipid metabolism.
  • the expression level of PGC1 ⁇ gene was significantly decreased in the walleye fish protein group in the soleus muscle compared with the casein group. On the other hand, there was no difference in the expression of PGC1 ⁇ gene between the two groups in the longus extensor muscle.
  • FIG. 9 shows the measurement results of the GLUT4 gene, which is an indicator of increased carbohydrate metabolism.
  • the expression level of the GLUT4 gene was significantly increased in the walleye fish protein group in the soleus muscle compared with the casein group.
  • the longus extensor there was no difference in GLUT4 gene expression between the two groups.
  • the collected blood is absorbed by a blood sugar measuring chip (Life Scan, One Touch Ultra), and a blood glucose analyzer (Roche, ACCU-CHEK) Analysis was performed with an active glucose meter. At this time, the rats were ingesting 15-30 g of food per day.
  • FIG. 10 shows the results of changes in blood glucose level by the glucose tolerance test. Compared with the casein group, the increase in blood glucose level was significantly suppressed in the walleye fish protein group. Also in the comparison of the integral values for 120 minutes, it was confirmed that the increase in blood glucose level was significantly suppressed in the walleye fish protein group compared with the casein group.
  • walleye fish protein has an action of suppressing an increase in blood sugar level. It is inferred that the long-term administration of walleye pollock fish protein changed the muscle fiber type in the direction that the slow muscles become faster, and increased the utilization of carbohydrates in the muscles, resulting in a decrease in blood glucose level.
  • 5-week-old male SD rats (obtained from Shimizu Experimental Materials Co., Ltd.) were divided into walleye fish protein group, soy protein group, egg white protein group, casein group, and whey group. Ad libitum.
  • a soy protein contained in the soy protein group feed a product of Fuji Oil Co., Ltd. was used.
  • the egg white protein contained in the feed of the egg white protein group was a product of Daiichi Kasei Co., Ltd.
  • the whey contained in the whey group feed was Daiichi Kasei Corporation.
  • the casein contained in the feed of the casein group was from New Zealand Dairy Board.
  • One group consisted of 10 rats, and the rats were ingested for 8 weeks continuously, then dissected and the tissue weight was measured. At this time, the rats were ingesting 15-30 g of food per day.
  • FIG. 11 and FIG. 12 show the results of measuring the weight of the puffer muscle and the long ankle extensor, which are representative of the fast muscles.
  • the walleye fish protein group significantly increased the weights of the gluteal and long-knee extensor muscles, which are representative of fast muscles.
  • the weight of the long rib extensor was significantly increased compared to the whey group.
  • the walleye fish protein group tended to increase the weight of the puffer muscle and the long calf extensor muscle, but no significant difference was observed.
  • the result of measuring the weight of the soleus which is representative of the slow muscle is shown in FIG.
  • the walleye fish protein group significantly increased the weight of the soleus muscle, which is representative of the slow muscle.
  • the walleye fish protein group tended to increase the weight of the soleus muscle, but no significant difference was observed.
  • walleye pollack fish meat protein has a stronger muscle-enhancing action than soybean protein, egg white protein, casein, and whey proteins after long-term administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un développeur de la masse musculaire. La présente invention concerne également des aliments présentant un effet développeur de la masse musculaire. Les inventeurs se sont concentrés sur les effets que la protéine du sandre exerce sur la fonction physiologique, et à la suite de recherches répétées, il a été découvert que la protéine du sandre présente un effet développeur de la masse musculaire, ce qui a mené à la présente invention. De manière spécifique, la présente invention concerne un développeur de la masse musculaire à spécificité musculaire contenant une protéine de poisson appartenant aux Gadiformes, et un développeur de la masse musculaire qui transforme les muscles à contractions lentes en muscles à contractions rapides. La présente invention concerne également des aliments contenant une protéine de poisson appartenant aux Gadiformes.
PCT/JP2011/069276 2010-08-26 2011-08-26 Développeur de la masse musculaire WO2012026575A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012530734A JP5838161B2 (ja) 2010-08-26 2011-08-26 筋肉増強剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010-190137 2010-08-26
JP2010190137 2010-08-26
JP2011108817 2011-05-13
JP2011-108817 2011-05-13

Publications (1)

Publication Number Publication Date
WO2012026575A1 true WO2012026575A1 (fr) 2012-03-01

Family

ID=45723564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/069276 WO2012026575A1 (fr) 2010-08-26 2011-08-26 Développeur de la masse musculaire

Country Status (2)

Country Link
JP (2) JP5838161B2 (fr)
WO (1) WO2012026575A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014062068A (ja) * 2012-09-21 2014-04-10 Nippon Suisan Kaisha Ltd 廃用性筋萎縮の予防又は治療剤
WO2015056619A1 (fr) * 2013-10-16 2015-04-23 日本水産株式会社 Peptide ou sel d'addition d'acide de celui-ci, aliment et boisson, et composition destinée à prévenir le diabète et autre
WO2017001515A1 (fr) * 2015-06-30 2017-01-05 Firmenich Sa Peptides marins et santé musculaire
JP2017057175A (ja) * 2015-09-18 2017-03-23 株式会社保健科学研究所 筋肉増加剤
KR102171663B1 (ko) * 2020-07-28 2020-11-02 주식회사 씨웰 한약재의 유효성분을 포함하는 대구살 알약 단백질 공급원 및 그 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010014368A1 (en) * 1999-12-28 2001-08-16 Kikkoman Corporation And We-Pop Co., Ltd. High-protein food of plate form and process for producing the same
WO2007069716A1 (fr) * 2005-12-16 2007-06-21 Nippon Suisan Kaisha, Ltd. Composition ayant un effet d'inhibition d'accumulation de graisses viscerales

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274414A1 (fr) * 1999-06-11 2000-12-11 Universite Laval Proteine de poisson alimentaire a utiliser pour restaurer la fonction normale de l'insuline chez les personnes insulinoresistantes
JP2001069949A (ja) * 1999-09-06 2001-03-21 Nippon Meat Packers Inc 豚肉分解物及びそれを含有する食品
JP2002053489A (ja) * 2000-08-07 2002-02-19 Kaken Pharmaceut Co Ltd 筋肉増強剤・筋肉減衰の予防・治療剤
EP1604671A4 (fr) * 2003-02-26 2006-03-29 Kyowa Hakko Kogyo Kk Agent de formation musculaire et agent de prevention et de soins en cas d'affaiblissement musculaire
JP2005261203A (ja) * 2004-03-16 2005-09-29 Japan Science & Technology Agency 骨格筋の組成及び量を改善する薬剤をスクリーニングする方法
JP2009507044A (ja) * 2005-09-09 2009-02-19 マレー ゴールバーン コーオペラティブ コー リミテッド 乳由来組成物、及び筋肉量または筋力を増強するための使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010014368A1 (en) * 1999-12-28 2001-08-16 Kikkoman Corporation And We-Pop Co., Ltd. High-protein food of plate form and process for producing the same
WO2007069716A1 (fr) * 2005-12-16 2007-06-21 Nippon Suisan Kaisha, Ltd. Composition ayant un effet d'inhibition d'accumulation de graisses viscerales

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XPMIZUSHIGE, T. ET AL.: "Fast-twitch muscle hypertrophy partly induces lipid accumulation inhibition with Alaska pollack protein intake in rats", BIOMED RES, vol. 31, no. 6, December 2010 (2010-12-01), pages 347 - 352 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014062068A (ja) * 2012-09-21 2014-04-10 Nippon Suisan Kaisha Ltd 廃用性筋萎縮の予防又は治療剤
WO2015056619A1 (fr) * 2013-10-16 2015-04-23 日本水産株式会社 Peptide ou sel d'addition d'acide de celui-ci, aliment et boisson, et composition destinée à prévenir le diabète et autre
JP5925391B2 (ja) * 2013-10-16 2016-05-25 日本水産株式会社 ペプチド又はその酸付加塩、飲食品、及び糖尿病予防等の組成物
WO2017001515A1 (fr) * 2015-06-30 2017-01-05 Firmenich Sa Peptides marins et santé musculaire
JP2017057175A (ja) * 2015-09-18 2017-03-23 株式会社保健科学研究所 筋肉増加剤
KR102171663B1 (ko) * 2020-07-28 2020-11-02 주식회사 씨웰 한약재의 유효성분을 포함하는 대구살 알약 단백질 공급원 및 그 제조방법

Also Published As

Publication number Publication date
JP6109909B2 (ja) 2017-04-05
JP5838161B2 (ja) 2015-12-24
JP2016073292A (ja) 2016-05-12
JPWO2012026575A1 (ja) 2013-10-28

Similar Documents

Publication Publication Date Title
JP6109909B2 (ja) 筋肉増強剤
Lollo et al. Probiotic yogurt offers higher immune-protection than probiotic whey beverage
Liu et al. Angiotensin converting enzyme (ACE) inhibitory, antihypertensive and antihyperlipidaemic activities of protein hydrolysates from Rhopilema esculentum
KR102240196B1 (ko) 신규한 락토바실러스 파라카세이 균주
JP2009173634A (ja) ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤
KR102315134B1 (ko) 장기능 개선용 발효 키위 분말 및 이의 제조방법
AU2015364473B2 (en) Grape products for nonalcoholic fatty liver disease and other uses
Milan et al. Digestion and postprandial metabolism in the elderly
JP2006304792A (ja) 内臓脂肪蓄積抑制食品
US8722614B2 (en) Adiponectin production enhancer
Liu et al. Hydrolyzed peptides from purple perilla (Perilla frutescens L. Britt.) seeds improve muscle synthesis and exercise performance in mice
CN109259243A (zh) 降三高的组合物及其制备方法和应用
CN114128890A (zh) 营养补充性组合物
JP5156330B2 (ja) 脂肪組織重量減少剤
JP2010105946A (ja) 筋タンパク質増強剤及びこれを含む医薬品または食品
Taha et al. Bio-logical activities of sunflower protein hydrolysate
JP6518189B2 (ja) 脂質代謝促進剤
JPWO2015022962A6 (ja) 脂質代謝促進剤
CN108430580B (zh) 诱导饱腹感的方法
JP2007008920A (ja) 生活習慣病改善剤
JP6418579B2 (ja) ホタテ貝外套膜のタンパク質分解物を有効成分とする脂質吸収促進剤及びこれを含む飲食品
Giromini et al. Milk proteins: Their role in cardiovascular health
KR102575452B1 (ko) 간 기능 개선 활성을 갖는 균주 및 이의 용도
JP2008179609A (ja) 血中アディポネクチン増加剤
JP5870181B1 (ja) 血清コレステロール値及び／又は血中脂質値の改善剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11820035

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012530734

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11820035

Country of ref document: EP

Kind code of ref document: A1